# Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma

> **NCT04314245** · — · COMPLETED · sponsor: **AnchorDx Medical Co., Ltd.** · enrollment: 1170 (actual)

## Conditions studied

- Urothelial Carcinoma
- Bladder Cancer

## Interventions

- **OTHER:** Active Comparator: Pathology
- **OTHER:** Active Comparator: Clinical Diagnosis
- **OTHER:** Active Comparator: Clinical diagnosis
- **OTHER:** Genetic test: AnchorDx's urine DNA methylation/somatic mutation profiling assay

## Key facts

- **NCT ID:** NCT04314245
- **Lead sponsor:** AnchorDx Medical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-01
- **Primary completion:** 2021-11-30
- **Final completion:** 2022-08-31
- **Target enrollment:** 1170 (ACTUAL)
- **Last updated:** 2023-05-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04314245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04314245, "Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04314245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*